Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Julio C Chavez

Showing results (11-20 of 132) with videos related to

Pageof 14
Sort By:
Core Evidence|May 30, 2013
Ibrutinib: an evidence-based review of its potential in the treatment of advanced chronic lymphocytic leukemiaJulio C Chavez, Eva Sahakian, Javier Pinilla-Ibarz
Expert Opinion on Emerging Drugs|August 31, 2023
Emerging synthetic drugs for the treatment of diffuse large B-cell lymphomaNing Dong, Lucia Perez-Lamas, Julio C Chavez
Expert Opinion on Biological Therapy|August 21, 2023
Tisagenlecleucel: CAR-T cell therapy for adult patients with relapsed or refractory follicular lymphomaAditi Saha, Khushali Jhaveri, Humaira Sarfraz, et al.
Therapeutic Advances in Hematology|April 26, 2019
CAR T-cell therapy for B-cell lymphomas: clinical trial results of available productsJulio C Chavez, Christina Bachmeier, Mohamed A Kharfan-Dabaja
Transplantation and Cellular Therapy|June 14, 2025
Evaluating the Role of CAR-T Cell Therapy in the Context of Current Therapy Options for Patients With Relapsed or Refractory Follicular LymphomaJulio C Chavez, Marc S Hoffmann, Leslie L Popplewell
Cancer Management and Research|May 8, 2023
Axicabtagene Ciloleucel in the Management of Follicular Lymphoma: Current Perspectives on Clinical Utility, Patient Selection and Reported OutcomesRazan Mohty, Mohamed A Kharfan-Dabaja, Julio C Chavez
Expert Opinion on Biological Therapy|January 9, 2025
Should CAR-T cell therapy be considered a standard of care for patients with refractory diffuse large B-cell lymphoma in second line treatment?Lucia Perez-Lamas, Jose Sandoval-Sus, Julio C Chavez
Targeted Oncology|June 19, 2024
Moving T-Cell Therapies into the Standard of Care for Patients with Relapsed or Refractory Follicular Lymphoma: A ReviewNathan Hale Fowler, Julio C Chavez, Peter A Riedell
Hematology/Oncology and Stem Cell Therapy|June 17, 2019
Cytokine release syndrome and neurologic toxicities associated with chimeric antigen receptor T-cell therapy: A comprehensive review of emerging grading modelsJulio C Chavez, Michael D Jain, Mohamed A Kharfan-Dabaja
Leukemia & Lymphoma|May 19, 2026
From immunomodulators (IMiDs) to cereblon E3 ligase modulator (CELMoDs): the evolution of cereblon modulators in lymphoma therapyAditi Saha, Khushali Jhaveri, Guilherme F Perini, et al.
Pageof 14

Showing results (11-20 of 132) with videos related to

Sort By:
Pageof 14
Core Evidence|May 30, 2013
Ibrutinib: an evidence-based review of its potential in the treatment of advanced chronic lymphocytic leukemiaJulio C Chavez, Eva Sahakian, Javier Pinilla-Ibarz
Expert Opinion on Emerging Drugs|August 31, 2023
Emerging synthetic drugs for the treatment of diffuse large B-cell lymphomaNing Dong, Lucia Perez-Lamas, Julio C Chavez
Expert Opinion on Biological Therapy|August 21, 2023
Tisagenlecleucel: CAR-T cell therapy for adult patients with relapsed or refractory follicular lymphomaAditi Saha, Khushali Jhaveri, Humaira Sarfraz, et al.
Therapeutic Advances in Hematology|April 26, 2019
CAR T-cell therapy for B-cell lymphomas: clinical trial results of available productsJulio C Chavez, Christina Bachmeier, Mohamed A Kharfan-Dabaja
Transplantation and Cellular Therapy|June 14, 2025
Evaluating the Role of CAR-T Cell Therapy in the Context of Current Therapy Options for Patients With Relapsed or Refractory Follicular LymphomaJulio C Chavez, Marc S Hoffmann, Leslie L Popplewell
Cancer Management and Research|May 8, 2023
Axicabtagene Ciloleucel in the Management of Follicular Lymphoma: Current Perspectives on Clinical Utility, Patient Selection and Reported OutcomesRazan Mohty, Mohamed A Kharfan-Dabaja, Julio C Chavez
Expert Opinion on Biological Therapy|January 9, 2025
Should CAR-T cell therapy be considered a standard of care for patients with refractory diffuse large B-cell lymphoma in second line treatment?Lucia Perez-Lamas, Jose Sandoval-Sus, Julio C Chavez
Targeted Oncology|June 19, 2024
Moving T-Cell Therapies into the Standard of Care for Patients with Relapsed or Refractory Follicular Lymphoma: A ReviewNathan Hale Fowler, Julio C Chavez, Peter A Riedell
Hematology/Oncology and Stem Cell Therapy|June 17, 2019
Cytokine release syndrome and neurologic toxicities associated with chimeric antigen receptor T-cell therapy: A comprehensive review of emerging grading modelsJulio C Chavez, Michael D Jain, Mohamed A Kharfan-Dabaja
Leukemia & Lymphoma|May 19, 2026
From immunomodulators (IMiDs) to cereblon E3 ligase modulator (CELMoDs): the evolution of cereblon modulators in lymphoma therapyAditi Saha, Khushali Jhaveri, Guilherme F Perini, et al.
Pageof 14